ACR-368 plus low-dose gemcitabine for advanced head and neck cancer
Treatments studied
Part of Cancer clinical trials.
This study tests a new combination of two drugs, ACR-368 and low-dose gemcitabine, for people with head and neck cancer that has come back or spread. The goal is to see if this treatment can help when immunotherapy or other therapies haven't worked.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have head and neck cancer that has come back or spread (recurrent/metastatic) from areas like the mouth, throat, voice box, or the HPV-positive unknown primary type.
- You have already had one treatment with immunotherapy (like Keytruda or Opdivo), or you cannot have immunotherapy because of an autoimmune disease or need for high-dose steroids.
- You have tumor tissue (or are willing to have a biopsy) so we can test key markers to see if this treatment is right for you.
- Your daily activities are not too limited (ECOG 0 or 1) and you have at least one tumor that can be measured on scans.
- You do not have serious heart problems, untreated brain metastases, or another active cancer within the last 3 years (except some low-risk ones).
- You are willing to use effective birth control if needed, and you haven't had cancer treatment or radiation within 2-4 weeks before starting.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new combination treatment for head and neck cancer that has come back or spread and has a specific genetic change (CDKN2A mutation). The treatment combines an antibody-drug conjugate (a targeted therapy) with a CDK4/6 inhibitor (a drug that helps stop cancer cells from dividing). It may help people who have already tried standard treatments like immunotherapy or chemotherapy.
This trial tests a new combination of two investigational drugs (adebrelimab and dalpiciclib) given before surgery for locally advanced head and neck cancer that is not linked to HPV. The goal is to see if these drugs can shrink the tumor and possibly improve outcomes.
This study tests whether adding two different drugs (nimotuzumab and benmelstobart) to standard radiation therapy after surgery can help improve outcomes for people with intermediate-risk head and neck cancer. It looks at whether the combination slows cancer growth or reduces the chances of it coming back.
This trial tests a combination of chemotherapy directly into an artery, radiation, and immunotherapy for advanced head and neck cancer. It may offer a new treatment option for people whose cancer hasn't spread to other parts of the body.
This trial tests a combination of three immunotherapy drugs (PD-L1 t-haNK, NAI IL-15sa, and cetuximab) for people with head and neck squamous cell carcinoma that has spread or cannot be cured. The goal is to see if this treatment can shrink tumors or slow the disease.
This trial tests a new immunotherapy drug called AK104 (cadonilimab) combined with low-dose radiation for people with head and neck or nasopharyngeal cancer that has come back or spread and no longer responds to first treatment. The goal is to see if this combination can shrink tumors or stop them from growing.
Hear when a new Head and Neck Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.